Meta-Analysis of Chinese Patent Medicine Combined with Zoledronic Acid in the Treatment of Primary Osteoporosis

  • Bin Yao Shaanxi University of Traditional Chinese Medicine
  • Wulin Kang Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine
  • Puwei Yuan Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine
  • Zhankui Wang Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine
  • Wenbo Huang Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine
  • Wulin Kang Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine
DOI: https://doi.org/10.18686/aem.v11i3.236
Keywords: Chinese Patent Medicine, Zoledronic Acid, System Evaluation, Primary Osteoporosis, Randomized Controlled Trial

Abstract

Objective: To systematically evaluate the safety and efficacy of Chinese patent medicine combined with zoledronic acid in the treatment of primary osteoporosis. Methods: CnKI, VIP, Wanfang Database, Chinese Biomedical literature database, PubMed, Web of Science, The Cochrane Library, Embase and CnKI were searched by computer RCTs of clinical randomized controlled trials of Chinese patent medicine combined with zoledronic acid in the treatment of primary osteoporosis in Embase database were retrieved from the database construction to April 1, 2022, and meta-analysis was performed using RevMan 5. 3 software. Results: A total of 14 RCTs were included, and the results of meta-analysis showed that:Compared with the control group, Chinese patent medicine combined with zoledronic acid had significant effects on the improvement of total clinical response rate, VAS score, MDL score, lumbar vertebra bone mineral density, femoral neck bone mineral density, Ward's triangle bone mineral density, osteocalcin and ALP, and significantly reduced alkaline phosphatase, with statistically significant differences. It had no significant effect on serum phosphorus, calcium and adverse reactions (P >0. 05). Conclusion: The safety and efficacy of Chinese patent medicine combined with zoledronic acid in the treatment of POP are clear, but the quality of the included studies is limited, and more high-quality studies are needed to enhance the evaluation evidence.

References

[1] Xia WB, Zhang ZL, Lin H, et al. Clinical guidelines for the diagnosis and treatment of primary osteoporosis [J]. Chin J Osteoporosis, 2017, 25 (5): 413-444.

[2] Ge JR, Wang HM, Zheng HX, et al. Expert consensus on prevention and treatment of primary osteoporosis with Traditional Chinese medicine (2020)[J]. Chinese Journal of Osteoporosis.

[3] Liu Y, Xu JW, Li MY, et al. Zoledronic Acid for Periprosthetic Bone Mineral Density Changes in Patients with Osteoporosis After Hip Arthroplasty—An Updated Meta-Analysis of Six Randomized Controlled Trials [J]. Frontiers in Medicine, 2021, 8.
Published
2022-11-03
Issue
Vol 11 No 3 (2022)
Section
Original Research Article

Copyright (c) 2022 Bin Yao

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Authors submitting to USP journals agree to publish their manuscript under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0) where authors agree to allow third parties to share their work (copy, distribute, transmit) and to adapt it, under the condition that the authors are given credit, and that in the event of reuse or distribution, the terms of this license are made clear

Authors retain copyright of their work, with first publication rights (online and print) granted to Universe Scientific Publishing or the owner of the journal in question.